Literature DB >> 21475478

Role of Integrated PET/CT Fusion in Lung Carcinoma.

S C Joshi1, Ishita Pant, F A Khan, A N Shukla, K Gokula.   

Abstract

Positron emission tomography has emerged as an important diagnostic tool in the management of lung cancers. PET is sensitive in the detection of lung cancer, but FDG (2-deoxy-2-18fluro-D-glucose) is not tumor specific and may accumulate in a variety of non-malignant conditions occasionally giving false negative result. The addition of CT to PET improves specificity foremost, but also sensitivity in tumor imaging. Thus, PET/CT fusion images are a more accurate test than either of its individual components and are probably also better than side-by-side viewing of images from both modalities. PET/CT fusion images are useful in differentiating between malignant and benign disease, fibrosis and recurrence, staging and in changing patient management to a more appropriate therapy. With analysis and discussion, it appears that PET/ CT fusion images have the potential to dramatically improve our ability to manage the patients with lung cancer and is contributing to our understanding of cancer cell biology and in the development of new therapies.

Entities:  

Keywords:  CAT scan (CT); Lung carcinoma; Positron emission tomography (PET)

Year:  2008        PMID: 21475478      PMCID: PMC3068710     

Source DB:  PubMed          Journal:  Int J Health Sci (Qassim)        ISSN: 1658-3639


  26 in total

1.  Side-by-side reading of PET and CT scans in oncology: which patients might profit from integrated PET/CT?

Authors:  Patrick Reinartz; Franz-Josef Wieres; Wolfram Schneider; Alexander Schur; Ulrich Buell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-10       Impact factor: 9.236

Review 2.  Positron-emitting isotopes produced on biomedical cyclotrons.

Authors:  Paul McQuade; Douglas J Rowland; Jason S Lewis; Michael J Welch
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

Review 3.  State-of-the-Art FDG-PET imaging of lung cancer.

Authors:  Matthew D Gilman; Suzanne L Aquino
Journal:  Semin Roentgenol       Date:  2005-04       Impact factor: 0.800

4.  PET-CT: accuracy of PET and CT spatial registration of lung lesions.

Authors:  Christian Cohade; Medhat Osman; Laura N T Marshall; Richard N T L Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-01       Impact factor: 9.236

5.  Clinical Applications of [(15)O] H(2)O PET Activation Studies.

Authors:  David C. Reutens; Richard G. Bittar; Henri Tochon-Danguy; Andrew M. Scott
Journal:  Clin Positron Imaging       Date:  1999-05

Review 6.  18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.

Authors:  Lale Kostakoglu; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

7.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

Authors:  Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

8.  Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.

Authors:  S S Gambhir; C K Hoh; M E Phelps; I Madar; J Maddahi
Journal:  J Nucl Med       Date:  1996-09       Impact factor: 10.057

9.  The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer.

Authors:  J D Kiffer; S U Berlangieri; A M Scott; G Quong; M Feigen; W Schumer; C P Clarke; S R Knight; F J Daniel
Journal:  Lung Cancer       Date:  1998-03       Impact factor: 5.705

10.  Monte Carlo-based lung cancer treatment planning incorporating PET-defined target volumes.

Authors:  Indrin J Chetty; Shaneli Fernando; Marc L Kessler; Daniel L McShan; Cassandra Brooks; Randall K Ten Haken; Feng-Ming Spring Kong
Journal:  J Appl Clin Med Phys       Date:  2005-11-21       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.